A. Ocampo

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir‐boosted saquinavir. The CIVSA Study *

M. Arnedo, T. Pumarola, J. Mallolas, 2007, HIV medicine.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

High Incidence of Non-B and Recombinant HIV-1 Strains in Newly Diagnosed Patients in Galicia, Spain: Study of Genotypic Resistance

M. Thomson, L. Pérez-Alvárez, A. Aguilera, 2002, Antiviral therapy.

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

R. Paredes, D. Podzamczer, M. Noguera-Julián, 2020, The Journal of antimicrobial chemotherapy.

Effect of simplification from protease inhibitors to boosted atazanavir‐based regimens in real‐life conditions

J. González-García, V. Asensi, R. Rubio, 2010, HIV medicine.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

J. De La Torre, J. Prada, S. Reus, 2018, The Journal of antimicrobial chemotherapy.

Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119

J. De La Torre, E. Ribera, R. Palacios, 2023, HIV medicine.